CSL names ViiV CEO Deborah Waterhouse as its new chief executive

· Health · United Kingdom · Australia

Deborah Waterhouse is leaving GSK after a 30-year career to become CEO of CSL, departing her role as chief executive of ViiV Healthcare, the UK pharma's HIV specialist. Endpoints News reported the move. Waterhouse had led ViiV, which GSK controls and which focuses solely on HIV medicines. Her departure hands GSK a leadership change at one of its specialist units while giving CSL, a plasma-products and vaccines group, an executive with long experience in specialty pharma. The report did not detail the timing of the transition or Waterhouse's mandate at CSL.

Why it matters：Leadership changes at major plasma-products and specialty pharma groups can signal shifts in strategy for HIV and immunology portfolios.

Key points

  • Waterhouse spent 30 years at GSK.
  • She was CEO of ViiV Healthcare, GSK's HIV specialist.
  • She becomes CEO of CSL.

Sources (original reporting)

More stories from this day